**EQUITY RESEARCH - ANALYST MEETING** 

# PRARAM 9 HOSPITAL

THAILAND / HEALTH CARE SERVICES

PR9 TB



**FSSIA ESG rating** 





TARGET PRICE THB22.00 CLOSE THB14.00 **UP/DOWNSIDE** +57.1%

TP vs CONSENSUS

+1.9%

# Key takeaways from analyst meeting

#### **Highlights**

- เราได้รับข้อมูลเชิงบวกจากที่ประชุมนักวิเคราะห์หลังรายงานผลประกอบการ 3Q23
- ผู้บริหารคาดว่ารายได้จะโตดีทั้ง q-q และ y-y ใน 4Q23 พร้อมอัตรากำไรที่ปรับตัวดีขึ้น เนื่องจากต้นทุนคงที่ทรงตัวมาตั้งแต่ 3Q23 บริษัทฯ ตั้งเป้าให้รายได้โต 3-4% ในปี 2023 คิดเป็นรายได้ 1.2พัน ลบ. ใน 4Q23 (เทียบกับ 1.07พัน ลบ. ใน 3Q23)
- นอกจากนี้ผู้บริหารยังตั้งเป้าการเติบโตของรายได้ที่ 10% ในปี 2024 พร้อมอัตรากำไร สทธิที่ปรับตัวดีขึ้น
- การผ่าตัดปลูกถ่ายไตทำสถิติสูงสุดใหม่ที่ 88 ราย (ณ. กลางเดือน พ.ย.) เทียบกับ 86 รายในปี 2023
- บริษัทฯ คาดว่ารายได้จากผู้ป่วยจากต่างประเทศจะโตดีที่ 20% y-y พร้อมสัดส่วนรายได้ จากต่างประเทศที่เพิ่มจาก 14% เป็น 16% ในปี 2024 โดยได้ปัจจัยหนุนจากผู้ป่วยจาก ตลาด CLMV จีนและตะวันออกกลาง
- PR9 ได้จัดตั้งทีมการตลาดต่างประเทศใหม่เพื่อติดต่อตัวแทนในการส่งต่อผู้ป่วยชาว ตะวันออกกลางให้มากขึ้น บริษัทฯ คาดว่าทีมดังกล่าวจะเริ่มดำเนินงานเต็มกำลังได้ใน 1Q24
- PR9 กำลังปรับปรุงห้อง ICU และ CCU ขนาด 24 เตียงใน 4Q23 ปัจจัยดังกล่าวน่าจะ ช่วยเพิ่มจำนวนเตียงที่ใช้ในการดำเนินงานจาก 180 เป็น 204 เตียงภายในสิ้นปีนี้ นอกจากนี้โรงพยาบาลยังวางแผนเพิ่มเตียงผัป่วยในอีก 20 เตียงในปี 2024
- PR9 กำลังพิจารณาปรับค่าบริการขึ้นหลังปรับปรุง ตึก A แล้วเสร็จซึ่งน่าจะอยู่ในปี 2024

#### Recommendation

ราคาหุ้นของ PR9 ได้ปรับตัวลดลงแล้ว 17% ในช่วงเดือนที่ผ่านมาจากสภาวะตลาดที่ อ่อนแอ นับว่าเป็นโอกาสที่ดีในการซื้อโดยมีสมมติฐานจาก 1) แนวโน้มจำนวนวันในการ ใช้เตียงผู้ป่วยในขาขึ้นใน 4Q23; 2) การเติบโตของกำไรเมื่อเทียบ q-q และ y-y ใน 4Q23 พร้อมโอกาสที่จะทำสถิติสูงสุดใหม่; และ 3) การเติบโตในระดับสูงใหม่ที่อาจได้ จากผู้ป่วยชาวตะวันออกกลาง นอกจากนี้ PR9 ยังมีการซื้อขายในระดับการประเมินมูล ค่าที่ต่ำเพียง 18x ของค่า 2024E P/E

### **KFY STOCK DATA**

YE Dec (THB m)	2022	2023E	2024E	2025E
Revenue	4,107	4,153	4,491	4,765
Net profit	568	506	603	655
EPS (THB)	0.72	0.64	0.77	0.83
vs Consensus (%)	-	0.9	8.8	3.4
EBITDA	991	927	1,062	1,143
Recurring net profit	568	506	603	655
Core EPS (THB)	0.72	0.64	0.77	0.83
EPS growth (%)	127.8	(10.9)	19.2	8.7
Core P/E (x)	19.4	21.8	18.3	16.8
Dividend yield (%)	2.1	2.3	2.7	3.0
EV/EBITDA (x)	9.4	9.8	8.2	7.2
Price/book (x)	2.3	2.2	2.1	1.9
Net debt/Equity (%)	(36.1)	(38.8)	(43.6)	(47.7)
ROE (%)	12.6	10.4	11.6	11.8



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	(16.7)	(22.7)	(20.9)
Relative to country (%)	(14.6)	(16.9)	(8.9)
Mkt cap (USD m)			311
3m avg. daily turnover (USI	O m)		0.7
Free float (%)			59
Major shareholder	Khunying Potja	man Damap	ong (37%)
12m high/low (THB)		2	1.30/13.10
Issued shares (m)			786.30


Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969


PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

### **Exhibit 1: Non-Covid Thai patient revenue**




Sources: PR9; FSSIA estimates

Exhibit 3: EBITDA margin




Sources: PR9; FSSIA estimates

Exhibit 5: IPD average daily census (ADC)




Sources: PR9; FSSIA estimates

**Exhibit 2: International patient revenue** 



Sources: PR9; FSSIA estimates

Exhibit 4: Core profit



Sources: PR9; FSSIA estimates

**Exhibit 6: Middle East International marketing team** 



Sources: PR9; FSSIA estimates

# **Financial Statements**

Praram 9 Hospital

Profit and Loss (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
Revenue	2,987	4,107	4,153	4,491	4,765
Cost of goods sold	(2,172)	(2,724)	(2,789)	(2,985)	(3,156)
Gross profit	815	1,384	1,364	1,507	1,609
Other operating income	39	43	46	60	62
Operating costs	(557)	(735)	(789)	(826)	(867)
Operating EBITDA	590	991	927	1,062	1,143
Depreciation	(294)	(299)	(306)	(321)	(340)
Goodwill amortisation	-	-	-	` -	` -
Operating EBIT	297	692	621	741	803
Net financing costs	4	8	12	13	16
Associates	0	0	0	0	0
Recurring non-operating income	0	0	0	0	0
Non-recurring items	0	0	0	0	0
Profit before tax	300	700	632	754	819
Tax	(51)	(132)	(126)	(151)	(164)
Profit after tax	249	568	506	603	655
Minority interests	0	0	0	0	0
Preferred dividends	-	-	-	-	-
Other items	_	_	_	_	_
Reported net profit	249	568	506	603	655
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	249	568	506	603	655
Per share (THB)					
Recurring EPS *	0.32	0.72	0.64	0.77	0.83
Reported EPS	0.32	0.72	0.64	0.77	0.83
DPS	0.14	0.29	0.32	0.38	0.42
Diluted shares (used to calculate per share data)	786	786	786	786	786
Growth					
Revenue (%)	14.8	37.5	1.1	8.2	6.1
Operating EBITDA (%)	33.0	67.9	(6.5)	14.6	7.7
Operating EBIT (%)	28.5	133.3	(10.3)	19.3	8.5
Recurring EPS (%)	23.3	127.8	(10.9)	19.2	8.7
Reported EPS (%)	23.3	127.8	(10.9)	19.2	8.7
Operating performance			, ,		
Gross margin inc. depreciation (%)	27.3	33.7	32.8	33.6	33.8
Gross margin exc. depreciation (%)	37.1	41.0	40.2	40.7	40.9
Operating EBITDA margin (%)	19.8	24.1	22.3	23.6	24.0
Operating EBIT margin (%)	9.9	16.8	14.9	16.5	16.9
Net margin (%)	8.3	13.8	12.2	13.4	13.8
Effective tax rate (%)	17.0	18.9	20.0	20.0	20.0
Dividend payout on recurring profit (%)	44.2	40.2	50.0	50.0	50.0
Interest cover (X)	(79.4)	(84.0)	(54.0)	(56.3)	(50.5)
Inventory days	10.2	8.1	7.6	7.5	7.5
Debtor days	22.7	20.2	22.7	22.3	21.0
Creditor days	101.4	82.5	74.3	72.6	73.1
Operating ROIC (%)	7.7	18.1	16.4	19.5	21.4
ROIC (%)	7.5	17.4	15.3	18.2	20.0
ROE (%)	5.9	12.6	10.4	11.6	11.8
ROA (%)	5.0	10.5	8.7	9.8	10.0
* Pre exceptional, pre-goodwill and fully diluted	5.5		<b></b>	0.0	
Revenue by Division (THB m)	2021	2022	2023E	2024E	2025E
OPD patient revenue	1,620	2,383		2,570	2,726
IPD patient revenue	1,367	2,383 1,725	2,376 1,777	2,570 1,922	2,726
Sources: Praram 9 Hospital: FSSIA estimates	.,	.,. 20	.,	.,022	_,000

Sources: Praram 9 Hospital; FSSIA estimates

# **Financial Statements**

Praram 9 Hospital

Cash Flow (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
Recurring net profit	249	568	506	603	65
Depreciation	294	299	306	321	340
Associates & minorities	-	-	-	-	,
Other non-cash items	3 27	10	0 (10)	0 41	34
Change in working capital  Cash flow from operations	57 <b>4</b>	(5) <b>871</b>	(19) <b>793</b>	965	1,030
Capex - maintenance	(235)	(140)	(328)	(320)	(339
Capex - maintenance Capex - new investment	(233)	(140)	(326)	(320)	(339
let acquisitions & disposals	0	(150)	0	0	(
Other investments (net)	-	(100)	-	-	`
Cash flow from investing	(235)	(290)	(328)	(320)	(339
Dividends paid	(86)	(110)	(228)	(253)	(301
Equity finance	0	0	0	0	(00.
Debt finance	(2)	2	0	0	(
Other financing cash flows	Ó	0	0	0	(
Cash flow from financing	(88)	(108)	(228)	(253)	(301
Non-recurring cash flows	•	. ,	. ,		•
Other adjustments	0	0	0	0	(
let other adjustments	0	0	0	0	
Novement in cash	250	473	237	393	390
Free cash flow to firm (FCFF)	338.71	581.44	465.46	646.06	691.5
Free cash flow to equity (FCFE)	336.58	582.47	464.92	645.53	691.0
er share (THB)					
CFF per share	0.43	0.74	0.59	0.82	0.88
CFE per share	0.43	0.74	0.59	0.82	0.88
Recurring cash flow per share	0.69	1.11	1.03	1.18	1.2
Solonos Shoot (TUR m) Voor Ending Dog	2021	2022	20225	20245	2025
Balance Sheet (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025
angible fixed assets (gross)	5,565	5,638	5,965	6,285	6,62
.ess: Accumulated depreciation	(2,090)	(2,322)	(2,628)	(2,949)	(3,289
angible fixed assets (net)	3,475	3,315	3,337	3,336	3,33
ntangible fixed assets (net)	0	0	0	0	
ong-term financial assets	-	-	-	-	
nvest. in associates & subsidiaries	4	154	154	154	15
Cash & equivalents	1,244	1,717	1,954	2,347	2,73
VC receivable	212	243	274	274	27
nventories	56	51	53	56	6
Other current assets	90	12	12	13	1
Current assets	1,603	2,023	2,293	2,690	3,08
Other assets Fotal assets	55 5 4 2 7	65 5 550	65 5 840	65	6
Otal assets Common equity	5,137	<b>5,558</b> 4,735	<b>5,849</b> 5,013	<b>6,245</b> 5,363	<b>6,63</b> 5,71
Ainorities etc.	4,278 0	4,735	5,013	0,363	5,71
otal shareholders' equity	4,278	4,735	5,013	5,363	5,71
ong term debt	<b>4,276</b>	4,733	3, <b>013</b> 8	3,303 8	3,71
Other long-term liabilities	190	209	209	209	20
ong-term liabilities	196	217	217	217	20 <b>21</b>
VC payable	597	499	512	549	58
Short term debt	0	0	0	0	30
Other current liabilities	66	106	107	116	12
Current liabilities	663	606	619	665	70
otal liabilities and shareholders' equity	5,137	5,558	5,849	6,245	6,63
Net working capital	(305)	(299)	(280)	(321)	(356
nvested capital	3,230	3,235	3,276	3,233	3,19
Includes convertibles and preferred stock which is beir		.,	-, -	,	-, -
·					
Per share (THB)	F 44	0.00	0.00	0.00	7.0
Book value per share	5.44	6.02	6.38	6.82	7.2
angible book value per share	5.44	6.02	6.38	6.82	7.2
Financial strength	(00.0)	(00.4)	(0.0.0)	(40.0)	
let debt/equity (%)	(28.9)	(36.1)	(38.8)	(43.6)	(47.7
Net debt/total assets (%)	(24.1)	(30.8)	(33.3)	(37.5)	(41.1
Current ratio (x)	2.4	3.3	3.7	4.0	4.
CF interest cover (x)	(89.2)	(69.7)	(39.4)	(48.0)	(42.4
aluation	2021	2022	2023E	2024E	2025
Recurring P/E (x) *	44.2	19.4	21.8	18.3	16.
Recurring P/E @ target price (x) *	69.4	30.5	34.2	28.7	26.
Reported P/E (x)	44.2	19.4	21.8	18.3	16.
Dividend yield (%)	1.0	2.1	2.3	2.7	3
Price/book (x)	2.6	2.3	2.2	2.1	1.
Price/tangible book (x)	2.6	2.3	2.2	2.1	1
EV/EBITDA (x) **	16.6	9.4	9.8	8.2	7
V/EBITDA @ target price (x) **	27.2	15.7	16.6	14.1	12
- ' ' '					
EV/invested capital (x)	3.0	2.9	2.8	2.7	2.

Sources: Praram 9 Hospital; FSSIA estimates

# Praram 9 Hospital PCL (PR9 TB)



# Exhibit 7: FSSIA ESG score implication

54.08 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
****	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

# Exhibit 8: ESG – peer comparison

	FSSIA		Domestic ratings						Global ratings					Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Y	Υ	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
вн	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Y	Υ	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: <u>SETTRADE.com</u>; FSSIA's compilation

# Exhibit 9: ESG score by Bloomberg

FY ending Dec 31	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	_	2.33	2.43
BESG environmental pillar score	_	2.56	2.18
BESG social pillar score	_	1.36	1.52
BESG governance pillar score	_	4.13	4.46
ESG disclosure score	_	37.90	37.90
Environmental disclosure score	_	11.78	11.78
Social disclosure score	_	20.68	20.68
Governance disclosure score	_	81.10	81.10
Environmental			
Emissions reduction initiatives	No	Yes	Yes
Climate change policy	No	Yes	Yes
Climate change opportunities discussed	No	No	No
Risks of climate change discussed	No	No	No
GHG scope 1	_	0	C
GHG scope 2 location-based	_	4	6
GHG Scope 3	_	0	5
Carbon per unit of production	_	_	_
Biodiversity policy	No	No	No
Energy efficiency policy	No	Yes	Yes
Total energy consumption	_	7	13
Renewable energy use	_	_	_
Electricity used	_	_	_
Fuel used - natural gas	_	_	_

Sources: Bloomberg; FSSIA's compilation

Exhibit 10: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No
Waste reduction policy	No	Yes	Yes
Hazardous waste	_	_	_
Total waste	_	_	_
Waste recycled	_	_	_
Waste sent to landfills	_	_	_
Environmental supply chain management	No	No	No
Water policy	No	Yes	Yes
Water consumption	_	60	151
Social			
Human rights policy	Yes	Yes	Yes
Policy against child labor	No	Yes	Yes
Quality assurance and recall policy	No	Yes	Yes
Consumer data protection policy	No	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes
Gender pay gap breakout	No	No	No
Pct women in workforce	_	_	
Pct disabled in workforce	_	_	_
Business ethics policy	No	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes
Health and safety policy	No	Yes	Yes
Lost time incident rate - employees		_	
Total recordable incident rate - employees	_	1	0
Training policy	Yes	Yes	Yes
Fair remuneration policy	No	No	No
Number of employees – CSR	2,083	1,987	2,011
Employee turnover pct		11	13
Total hours spent by firm - employee training	14,566	13,462	66,852
Social supply chain management	No No	No No	No
Governance	140	140	140
Board size	10	10	9
No. of independent directors (ID)	4	7	6
No. of women on board	2	2	2
No. of non-executive directors on board	7	7	6
Company conducts board evaluations	Yes	Yes	Yes
No. of board meetings for the year	7	7	7
Board meeting attendance pct	97	100	89
	3	3	3
Board duration (years)  Director share ownership guidelines	No No	No No	
	56	56	No 57
Age of the youngest director	72	73	74
Age of the oldest director	7	5	5
No. of executives / company managers  No. of female executives	2		
		0 No.	0 No.
Executive share ownership guidelines	No	No 3	No
Size of audit committee	3		3
No. of ID on audit committee	3	3	3
Audit committee meetings	4	4	4
Audit meeting attendance %	100	100	100
Size of compensation committee	3	3	3
No. of ID on compensation committee	3	2	3
No. of compensation committee meetings	2	2	2
Compensation meeting attendance %	83	100	100
Size of nomination committee	3	3	3
No. of nomination committee meetings	2	2	2
Nomination meeting attendance %	83	100	100
Sustainability governance			
Verification type	No	No	No

 $Sources: Bloomberg; FSSIA's \ compilation$ 

# **Disclaimer for ESG scoring**

ESG score	Methodolog	1V			Rating				
The Dow		•	transparent, rules-based co	omponent selection	Be a member and invited to the annual S&P Global Corporate				
Jones Sustainability	process bas	ed on the com	panies' Total Sustainability al Corporate Sustainability	Scores resulting	Sustainability Assessment (CSA) for DJSI. Companies with an S&P Glob. ESG Score of less than 45% of the S&P Global ESG Score of the highest				
Indices (DJSI) By S&P Global			anies within each industry a	` '	scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.				
Sustainability		fies responsibil	lity in Environmental and S	ocial issues by	To be eligible for <b>THSI inclusion</b> , verified data must be scored at a				
Investment			ansparency in Governance		minimum of 50% for each indicator, unless the company is a part of DJSI				
List (THSI) by The Stock			preemptive criteria, with twee board members and exe		during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality.				
Exchange of	float of >150	) shareholders,	and combined holding mu	st be >15% of paid-	SETTHSI Index is extended from the THSI companies whose 1) market				
Thailand ( <u>SET</u> )			ialifying criteria include: 1) tors and free float violation:		capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI				
,	wrongdoing	related to CG,	social & environmental imparnings in red for > 3 years	pacts; 4) equity in	Index is a market capitalisation-weighted index, cap 5% quarterly weight at maximum, and no cap for number of stocks.				
CG Score			n in sustainable developme		Scores are rated in six categories: 5 for Excellent (90-100), 4 for Very				
by Thai Institute of			with support from the Stock s are from the perspective		Good (80-89), 3 for Good (70-79), 2 for Fair (60-69), 1 for Pass (60-69), and not rated for scores below 50. Weightings include: 1) the rights; 2) and				
Directors		n of operations		or a uma party, not	equitable treatment of shareholders (weight 25% combined); 3) the role of				
Association (Thai IOD)					stakeholders (25%); 4) disclosure & transparency (15%); and 5) board responsibilities (35%).				
AGM level	It quantifies	the extent to w	rhich shareholders' rights a	and equitable	The scores are classified into four categories: 5 for Excellent (100), 4 for				
By Thai			into business operations a		Very Good (90-99), 3 for Fair (80-89), and not rated for scores below 79.				
Investors Association			disclosed. All form importated annual						
(TIA) with		•	AGM procedures before the	•					
support from the SEC			nd after the meeting (10%), tinformation for voting; and 2) t						
trie SEC	rights can be	exercised. The se	econd assesses 1) the ease of a	attending meetings; 2)					
			nd 3) openness for Q&A. The to ntain discussion issues, resolu						
	results.)								
Thai CAC By Thai			Checklist include corruption ols, and the monitoring and		The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council				
Private Sector		•	s good for three years.	a developing of	approvals whose members are twelve highly respected individuals in				
Collective Action Against			e a CAC certified member stan an 18-month deadline to submi		professionalism and ethical achievements.				
Corruption	Certification, in	ncluding risk asse	essment, in place of policy and	control, training of					
(CAC)		n of policies to al	ablishment of whistleblowing ch I stakeholders.)	lanneis, and					
Morningstar			sk rating provides an overa		A company's ESG risk rating score is the sum of unmanaged risk. The				
<u>Sustainalytics</u>			of how much of a company' to be reviewed include corpora	•	more risk is unmanaged, the higher ESG risk is scored.				
	information, co	ompany feedback	er media, NGO reports/website k, ESG controversies, issuer fee		NEGL Low Medium High Severe				
	reports, and q	uality & peer revi	ews.		0-10 10-20 20-30 30-40 40+				
ESG Book	The ESG sc	ore identifies s	ustainable companies that	are better	The total ESG score is calculated as a weighted sum of the features				
			ver the long term. The metle ateriality including informati		scores using materiality-based weights. The score is scaled between 0				
			ljusted performance. Mater		and 100 with higher scores indicating better performance.				
		ng features wit a rolling quarte	th higher materiality and re	balancing these					
MSCI		<b>0</b> 1	<u> </u>	agement of financially	relevant ESG risks and opportunities. It uses a rules-based methodology to				
	identify indu	stry leaders an	d laggards according to the		isks and how well they manage those risks relative to peers.				
	AAA	8.571-10.000	Leader:	leading its industry in n	nanaging the most significant ESG risks and opportunities				
	ΑΑ Δ	7.143-8.570 5.714-7.142							
	A BBB	5.714-7.142 4.286-5.713			nal track record of managing the most significant ESG risks and opportunities relative to				
	BB	2.857-4.285		industry peers					
	В	1.429-2.856							
	ccc	0.000-1.428	Laggard:	lagging its industry bas	sed on its high exposure and failure to manage significant ESG risks				
Moody's ESG				ke into account ESG o	objectives in the definition and implementation of their strategy policies. It				
solutions	believes that	t a company in		its business model ar	d relatively outperforming its peers is better positioned to mitigate risks and				
Refinitiv ESG	Designed to	transparently a	and objectively measure a	company's relative ES	SG performance, commitment and effectiveness across 10 main themes,				
rating					100 on relative ESG performance and insufficient degree of transparency in = satisfactory; >50 to 75 = good; and >75 to 100 = excellent.)				
S&P Global			re is a relative score measurin the same industry classif		formance on and management of ESG risks, opportunities, and impacts ages from 0 to 100.				
Bloomberg	ESG Score				gregated Environmental, Social and Governance (ESG) performance. The				
					ancial materiality. The score is a weighted generalized mean (power mean) ned by the pillar priority ranking. Values range from 0 to 10; 10 is the best.				
Bloomberg	ESG Disclos	sure Score			berg ESG score. The score ranges from 0 for none to 100 for disclosure of				
		every data point, measuring the amount of ESG data reported publicly, and not the performance on any data point.							

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

#### **GENERAL DISCLAIMER**

### ANALYST(S) CERTIFICATION

#### Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

#### History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
20-Nov-2020 26-Apr-2021 16-Jul-2021	BUY BUY BUY	12.00 13.00 14.00	10-Jan-2022 22-Apr-2022 12-Jul-2022	BUY BUY BUY	15.00 16.50 18.00	11-Oct-2022 17-Jan-2023	BUY BUY	21.00 22.00

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Praram 9 Hospital	PR9 TB	THB 14.00	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.

Source: FSSIA estimates

#### **Additional Disclosures**

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 15-Nov-2023 unless otherwise stated.

# RECOMMENDATION STRUCTURE

#### Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price\* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

\* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

#### **Industry Recommendations**

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

#### **Country (Strategy) Recommendations**

**Overweight (O).** Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Neutral (N).** Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Underweight (U).** Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.